Get the Stockscreener App
23.47
1.32%
0.34
Apellis Pharmaceuticals Inc stock is traded at $23.47, with a volume of 490.28K.
It is up +1.32% in the last 24 hours and down -14.31% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$23.13
Open:
$23.64
24h Volume:
490.28K
Relative Volume:
0.21
Market Cap:
$2.96B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-11.56
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
-7.74%
1M Performance:
-14.31%
6M Performance:
-3.99%
1Y Performance:
-34.23%
1-Day Range:
$23.23
$23.79
1-Week Range:
$23.00
$25.42
52-Week Range:
$16.10
$37.84
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
23.45 | 2.92B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.99 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
593.23 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.97 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
726.87 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
339.82 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Value Recap: How correlated is Apellis Pharmaceuticals Inc to the S P500July 2025 Breakouts & Community Driven Trade Alerts - خودرو بانک
Apellis Pharmaceuticals, Inc. $APLS Shares Acquired by Woodline Partners LP - MarketBeat
Apellis Pharma VP Chopas sells $4.5k in shares - Investing.com
Tools to assess Apellis Pharmaceuticals Inc.’s risk profileJuly 2025 Trade Ideas & Real-Time Volume Trigger Notifications - newser.com
MACD Signal: Does Apellis Pharmaceuticals Inc stock have upside surprise potentialInsider Selling & Risk Controlled Stock Alerts - خودرو بانک
Market Outlook: How cyclical is Apellis Pharmaceuticals Inc.’s revenue streamMarket Performance Recap & High Accuracy Trade Alerts - خودرو بانک
Buyout Rumor: Will Apellis Pharmaceuticals Inc outperform the market in YEARDip Buying & Detailed Earnings Play Alerts - خودرو بانک
Apellis Pharmaceuticals, Inc. $APLS Shares Acquired by Goldman Sachs Group Inc. - MarketBeat
Treasury Yields: Can Apellis Pharmaceuticals Inc stock outperform in a bear marketJuly 2025 Institutional & Weekly High Conviction Trade Ideas - خودرو بانک
Stock Market Recap: Does GOODO have declining or rising EPSProfit Target & Technical Confirmation Trade Alerts - خودرو بانک
Aug Reactions: Is Apellis Pharmaceuticals Inc. stock showing strong momentum2025 Geopolitical Influence & Long-Term Safe Investment Ideas - خودرو بانک
30,191 Shares in Apellis Pharmaceuticals, Inc. $APLS Bought by Voleon Capital Management LP - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 4.1%Time to Sell? - MarketBeat
Trading Action: How cyclical is Apellis Pharmaceuticals Inc.’s revenue stream2025 Analyst Calls & Community Consensus Trade Alerts - خودرو بانک
Surprises Report: What is the PEG ratio of Apellis Pharmaceuticals IncJuly 2025 PreEarnings & Verified Trade Idea Suggestions - خودرو بانک
Chart Watch: Is Apellis Pharmaceuticals Inc subject to activist investor interestEarnings Recap Summary & Fast Gain Swing Alerts - خودرو بانک
FDA Approval and Strategic Deals Drive Apellis Pharmaceuticals’ Stock Higher for the Week - MSN
Octagon Capital Advisors LP Has $45.80 Million Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Royal Bank of Canada Sells 723,892 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Smart tools for monitoring Apellis Pharmaceuticals Inc.’s price actionMarket Sentiment Summary & Weekly Momentum Stock Picks - newser.com
What MACD and RSI say about Apellis Pharmaceuticals Inc.2025 EndofYear Setup & Fast Momentum Entry Tips - newser.com
Teza Capital Management LLC Makes New $259,000 Investment in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Bayforest Capital Ltd Boosts Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Focus Partners Advisor Solutions LLC Makes New $363,000 Investment in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
When Can We Expect A Profit From Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)? - Yahoo Finance
Alyeska Investment Group L.P. Buys New Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Granahan Investment Management LLC Raises Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Graham Capital Management L.P. Acquires New Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by AQR Capital Management LLC - MarketBeat
Northern Trust Corp Has $11.34 Million Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Activity Recap: What’s the beta of Apellis Pharmaceuticals Inc. stockPortfolio Value Report & Short-Term High Return Ideas - Lancaster City Council
Apellis Pharmaceuticals at Baird Conference: Strategic Insights in Healthcare By Investing.com - Investing.com Canada
Apellis Pharmaceuticals at Baird Conference: Strategic Insights in Healthcare - Investing.com
Is Apellis Pharmaceuticals Inc. stock a value trapBuy Signal & Low Drawdown Investment Strategies - beatles.ru
How Apellis Pharmaceuticals Inc. stock performs during market volatilityMarket Volume Report & Technical Buy Zone Confirmation - classian.co.kr
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) CAO Sells 548 Shares of Stock - MarketBeat
683 Capital Management LLC Cuts Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Order flow analysis tools used on Apellis Pharmaceuticals Inc.July 2025 Macro Moves & Real-Time Volume Triggers - Newser
PDT Partners LLC Acquires 57,471 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Aug Fed Impact: What is Apellis Pharmaceuticals Inc.’s valuation compared to sectorPortfolio Update Report & AI Driven Price Forecasts - خودرو بانک
Will Apellis Pharmaceuticals Inc. benefit from rising consumer demandJuly 2025 PreEarnings & Short-Term High Return Strategies - خودرو بانک
Canada Pension Plan Investment Board Purchases 1,013,500 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Landscape Capital Management L.L.C. Trims Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Analyzing net buyer seller activity in Apellis Pharmaceuticals Inc.2025 Market Overview & Verified High Yield Trade Plans - Newser
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):